Gilead Sciences Announces Phase 3 IDEAL Study Results for Livdelzi in PBC

Gilead Sciences reported detailed Phase 3 IDEAL study results for Livdelzi (seladelpar) in primary biliary cholangitis (PBC). A majority of treated participants met the study’s ALP normalization composite endpoint: alkaline phosphatase at or below the upper limit of normal and at least a 15% decrease from baseline. Gilead said the findings support Livdelzi as a second-line treatment option for a broad PBC population; the article provided no financial results or stock-price impact.